Core Viewpoint - Hangzhou Shenluo Medical Technology Co., Ltd. has completed a multi-hundred million RMB Series C financing round, led by Junlian Capital, with participation from existing shareholders including OrbiMed, Boyuan Capital, and Guotou Chuanghe [2]. Company Introduction - Hangzhou Shenluo Medical Technology Co., Ltd. is engaged in the research and development of medical devices related to neuroregulation and brain-computer interfaces, headquartered in Hangzhou, Zhejiang Province [2]. Product and Technology Overview - The company focuses on the development and commercialization of implantable neurostimulation devices and brain-computer interface technologies [2]. 1. **Spinal Cord Stimulation (SCS) System**: Approved by the National Medical Products Administration (NMPA) for chronic pain management, launched in early 2026 [2]. 2. **Peripheral Nerve Stimulation (PNS) System**: Currently in the registration application stage for peripheral nerve regulation treatments [3]. 3. **Tibial Nerve Stimulation (TNS) System**: Targets neuroregulation for urinary function-related diseases, part of the company's wireless micro-neuroregulation technology platform [4]. 4. **Brain-Computer Interface Technology**: Developing a closed-loop brain-computer interface system for applications in neural function recovery, including spinal cord injuries [7]. 5. **Sublingual Nerve Stimulation System**: Under development for the treatment of obstructive sleep apnea [8]. Product Registration Status - The company has received multiple medical device registration certificates from the National Medical Products Administration, including: - Spinal Cord Stimulation External Controller - Implantable Spinal Cord Stimulation Electrodes - Test Stimulator - Patient Controller for Spinal Cord Stimulation [9]. Financing History - The financing history includes: - March 2026: Series C round, amount undisclosed, led by Chengdu Junrongkang Venture Capital [10]. - April 2024: Series B+ round, multi-hundred million RMB, led by OrbiMed [10]. - October 2022: Series B round, approximately hundred million RMB, led by Guotou Chuanghe [10]. - January 2022: Series A round, multi-million RMB, led by Bodin Capital [10]. Patent Situation - The company holds several authorized patents related to neurostimulation devices and methods, including: - Manufacturing methods for stimulation electrodes - Control methods for electrical stimulation devices - Wireless power supply devices for neurostimulators [12].

Investment Rating - The report maintains a "Recommended" rating for the brain-computer interface industry, indicating a positive outlook for the sector's fundamentals and expected performance exceeding the benchmark index [2][8]. Core Insights - The brain-computer interface (BCI) has been included in the government work report for the first time, highlighting its status as one of the five future industries alongside future energy, quantum technology, embodied intelligence, and 6G, suggesting a significant policy shift and increased investment opportunities [1][5]. - The report emphasizes the importance of government policies in guiding the development of the BCI industry, with historical data showing that sectors mentioned in government work reports tend to perform well post-announcement [5][6]. - The BCI industry is expected to enter a critical period of accelerated technological iteration and diversified application scenarios in 2026, with a strong recommendation for investment in companies like Daozhi Technology and attention to firms like Leidi Ke and Hanwei Technology [6]. Industry Overview - The industry comprises 266 listed companies with a total market capitalization of 4,646.9 billion and a circulating market value of 4,012.1 billion, indicating a substantial presence in the market [2]. - The absolute performance of the industry shows a decline of 3.3% over one month but an increase of 10.5% over six months and 27.2% over twelve months, reflecting a positive long-term trend despite short-term fluctuations [4].

Core Insights - The article highlights the increasing focus of institutional investors on hard technology breakthroughs and performance certainty for investment opportunities in 2026 [4] Group 1: Institutional Research Trends - In late 2025 to early 2026, institutions conducted research on approximately 1,162 companies, with a total of 30,000 receptions from listed companies across various core industries [3] - The shift in focus from merely gathering data to understanding practical applications indicates a significant change in investment strategies [9] Group 2: Brain-Computer Interface (BCI) Focus - Brain-computer interface technology has emerged as a key area of interest, with companies like Xiangyu Medical, Aipeng Medical, and Meihao Medical frequently hosting inquiries from fund managers [5][6] - Institutions are particularly interested in the depth of collaboration with innovative BCI clients and the feasibility of mass production [7][8] Group 3: AI Computing Power and Applications - The focus on artificial intelligence has shifted from foundational models to the iteration of computing power and practical applications [10] - Companies like Zhongji Xuchuang attracted attention for their 1.6T optical module orders and technology advancements, reflecting a market shift towards evaluating technological iteration speed [10] Group 4: Commercial Aerospace and Semiconductor Focus - Commercial aerospace has gained significant attention, with institutions exploring various segments such as rocket manufacturing and satellite components [17] - In the semiconductor sector, institutions are focused on overcoming technical barriers, with companies like Haimei Information and Huaren Micro receiving extensive inquiries regarding their advanced process products [22][23] - The trend of institutions closely monitoring companies with promising earnings forecasts indicates a more rational investment approach, seeking high-quality targets with core competitiveness [26]

Core Insights - Brain-machine interface technology has made significant advancements, with companies like Neuralink demonstrating the ability to help severely disabled individuals regain communication capabilities through implanted devices [1] - Merge Labs, a newly established startup, aims to develop a non-invasive brain-machine interface using ultrasound technology, which could potentially treat mental and neurological disorders [1][2] Group 1: Company Overview - Merge Labs was founded in January this year and has secured $252 million in funding from investors, including OpenAI [1] - The company is exploring a new type of brain-machine interface technology that could not only decode information but also have therapeutic applications for conditions like depression and addiction [1] Group 2: Technology and Methodology - Traditional brain-machine interfaces rely on electrode arrays that require invasive surgeries, posing risks and uncertainties for long-term recovery [2] - Merge Labs utilizes functional ultrasound, which emits high-frequency sound waves to monitor blood flow changes in the brain, indirectly inferring neuronal activity [2] - This method is less invasive than traditional electrode implantation, as sensors can be placed beneath the skull or through a small opening, allowing for monitoring of multiple brain regions [2] Group 3: Advanced Techniques - Merge Labs is also investigating "sonogenetics," a technique that makes specific neurons more sensitive to ultrasound, enabling precise activation or inhibition of targeted neurons [3][4] - The combination of sonogenetics and ultrasound could lead to more personalized and accurate treatment options for neurological diseases, including potential applications in vision restoration and cancer treatment [4] Group 4: AI Involvement and Ethical Considerations - The significant investment in Merge Labs is closely tied to the involvement of artificial intelligence, which is expected to play a central role in analyzing complex brain signals obtained through ultrasound [5] - However, the integration of AI raises ethical and privacy concerns regarding the handling of sensitive brain data, questioning whether the technology is aimed solely at patient recovery or also at enhancing AI models [6] - There are inherent limitations to functional ultrasound, including a response time lag due to its reliance on blood flow changes, which may hinder real-time applications like speech decoding [6]

Core Viewpoint - The integration of AI and brain-computer interfaces (BCIs) is accelerating the commercialization growth cycle, driven by technological iterations and policy support under the 14th Five-Year Plan [1][3]. Group 1: Technology Development - BCIs enable bidirectional information transmission, creating a collaborative pathway between humans and machines, with core functions including neural signal interpretation and external device control [2]. - Various technological routes are developing in parallel: non-invasive methods are currently mainstream due to their ease of use and safety, while semi-invasive and invasive methods offer advantages in risk-efficiency and high spatial resolution, respectively [2]. - The deep integration of AI with BCIs is a significant trend, enhancing signal decoding precision and efficiency through machine learning algorithms, leading to the evolution towards a "brain-machine intelligent community" [2]. Group 2: Market Dynamics - The global competition in the BCI industry is intensifying, with the US focusing on invasive technologies and China making breakthroughs in non-invasive and language decoding fields, while also catching up in invasive technologies [3]. - Domestic policies are supporting the BCI industry through the 14th Five-Year Plan, establishing a comprehensive support system that includes technological innovation, application scenarios, and medical insurance payment [3]. - Capital investment in the BCI sector is expected to see significant growth by 2025, with a notable increase in financing events and amounts, indicating a trend towards early-stage investment and a concentration of capital in leading enterprises [3]. Group 3: Application Scenarios - The healthcare sector is currently the most established application area for BCIs, with successful implementations in hearing impairment, tremor treatment, and motor rehabilitation, supported by a robust medical insurance payment system [4]. - Other application scenarios are rapidly expanding, including consumer markets targeting both disabled and healthy populations, and industrial applications focusing on high-risk, high-precision tasks transitioning from experimental validation to commercialization [4]. - Leading companies are building competitive advantages through comprehensive R&D, industry-academia collaboration, and multi-scenario layouts, creating differentiated strengths in non-invasive technology applications and AI integration [4].

Group 1 - The "Brain-Computer Valley" has welcomed its first batch of resident companies, marking a significant step in the development of the brain-computer interface industry from research to large-scale and clustered growth [1][2] - The core innovation source of the "Brain-Computer Valley" is the Brain-Computer Interaction and Human-Machine Integration Haihe Laboratory, focusing on breakthroughs in key technologies, clinical transformation, and industrial application [1] - Tianjin Binhai High-tech Zone is one of the city's first pilot areas for future industries, with plans to optimize the innovation environment and enhance policy support to promote the construction of the "Brain-Computer Valley" [1] Group 2 - Tianjin Tiankai Development Group's Vice General Manager stated that the Tiankai Higher Education Science and Technology Innovation Park is a crucial platform for promoting technological innovation and achievement transformation [2] - The "Brain-Computer Valley" is positioned as an important outcome of the Tiankai Park's layout in frontier interdisciplinary fields, aiming to create an industrial ecosystem led by high-end research platforms and innovative enterprises [2] - Multiple cooperation agreements were reached during the event, covering aspects such as company residency, investment intentions, and strategic partnerships [3]

Core Insights - The establishment of the brain-computer interface (BCI) outpatient clinic at Wuxi People's Hospital offers new hope for patients suffering from neurological disorders, integrating multiple disciplines for comprehensive treatment [1][2] - The clinic utilizes both non-invasive and minimally invasive BCI technologies to provide diagnostic and therapeutic services for severe motor impairments, refractory neurological diseases, and mental health issues [2] Group 1: Clinic Operations - The BCI outpatient clinic officially opened on January 12, becoming the first platform in Wuxi to integrate BCI technology with multidisciplinary collaboration for precise diagnosis and treatment [1] - Patients can receive evaluations and treatment plans without the need to visit multiple departments, streamlining the healthcare process [1] Group 2: Patient Experiences - Patients have reported significant improvements in their conditions, such as the ability to walk independently after undergoing rehabilitation training guided by BCI technology [1] - The clinic's approach has provided families with renewed hope, as seen in the experiences shared by patients and their relatives [1] Group 3: Government Support and Future Plans - The Jiangsu provincial government has outlined plans to accelerate the promotion of new technologies and products by 2026, which includes the BCI technology [1] - The focus on "first sets" of equipment, new materials, and software indicates a supportive environment for innovative medical technologies [1] Group 4: Research and Development - The Wuxi Brain Science Innovation Demonstration Center is exploring various applications of BCI technology, including smart rehabilitation and human-machine interaction [2] - Collaborative efforts between strong brain technology and local government aim to develop diverse application scenarios for BCI technology in healthcare and industry [2]

Core Viewpoint - The National Medical Insurance Administration is transforming its role from traditional fund management to a strategic hub that connects public health needs with pharmaceutical industry development, emphasizing dual functions of "social security + innovation empowerment" [1][2]. Group 1: Fund Support and Expenditure - During the 14th Five-Year Plan period, the total expenditure of the medical insurance fund is projected to reach 13 trillion yuan, with an average annual growth of 10%, providing stable financial support for innovation [2]. - The adjustment cycle for the medical insurance catalog has been compressed from 8 years to 1 year, focusing on new drugs launched within the last 5 years, with 98% of new effective drugs expected to be included in the catalog by 2024 [2]. - Over the past 8 years, more than 900 new drugs have been added, with 80% of new drugs being included in the payment scope within 2 years of their market launch, driving drug sales exceeding 600 billion yuan [2]. Group 2: Price Governance and Innovation Support - The establishment of the first national drug price registration network aims to achieve low drug prices through centralized procurement and catalog negotiations, while also supporting the application of innovative technologies such as surgical robots and digital customized imaging [2]. - The medical insurance department has proactively focused on the development of cutting-edge medical technologies, with the support process for brain-computer interface technology serving as a typical example [2][3]. - In March 2025, the medical insurance department established pricing and charging standards for brain-computer interfaces, addressing payment challenges for technology applications [2]. Group 3: Future Outlook and Strategic Initiatives - The medical insurance department is also incorporating a range of new technologies and drugs, such as remote operations, proton heavy ion therapy, and CAR-T tumor treatment, into its support framework, ensuring that the public benefits from innovative outcomes [3]. - The department is actively building international platforms to promote Chinese pharmaceutical innovations globally, while real-world comprehensive value evaluation serves as crucial evidence for medical insurance decision-making [3]. - Looking ahead to the 15th Five-Year Plan, the medical insurance department will continue to deepen its dual-driven strategy of "policy guidance" and "value evaluation," optimizing payment policies for innovative technologies like brain-computer interfaces [3].

Group 1 - The article discusses the challenges faced by new technologies and products in entering the market due to a lack of application cases and validation, leading to the phenomenon of "heroes having no place to showcase their skills" [1] - The implementation of the "Opinions on Accelerating Scene Cultivation and Open Promotion of Large-Scale Application of New Scenes" aims to address these issues by providing a platform for new technologies and products to be tested and validated in real-world scenarios [1] - The article emphasizes the importance of creating real application scenarios to facilitate the industrialization process of emerging technologies [1] Group 2 - The article highlights the role of a public training platform in reducing the initial investment costs for startups, allowing them to train robots in realistic environments [5][6] - The training process generates valuable data that supports algorithm iteration, which is crucial for the advancement of robotics technology [5][6] - The article mentions that the government is providing policy support to lower the barriers for the application of new technologies, facilitating the transition from training to real-world application [6] Group 3 - The article outlines the development stages of new technologies, emphasizing the need for feasibility validation in real scenarios and the importance of sustainable business models [8] - It discusses the "West Brain Valley" in Chengdu, which is fostering the growth of brain-computer interface companies and facilitating the application of cutting-edge technologies in clinical settings [10] - The article points out that systematic verification in real scenarios is essential for both technical and commercial validation of new technologies [12] Group 4 - The article describes the challenges faced by autonomous driving technologies, including regulatory and safety concerns, and the need for open testing environments [14][16] - It highlights the efforts made by Wuhan to create a supportive infrastructure for intelligent connected vehicles, including the establishment of a testing ground and regulatory reforms [14][16] - The article notes that the integration of government guidance, enterprise leadership, and market operations has created a strong ecosystem for innovation in the automotive industry [17] Group 5 - The article concludes that scenes have become a key innovation resource, acting as a bridge between technology and industry, and promoting the large-scale commercialization of new technologies and products [19] - It emphasizes China's advantages in having a vast market and rich application scenarios, which can accelerate the transition of new technologies from laboratories to everyday life [19] - The implementation of various measures is expected to stimulate innovation and drive high-quality economic development [19]

Economic Growth Targets - The main expected target for Shanghai's economic growth in 2023 is around 5% [2][3] - By 2025, Shanghai's GDP is projected to reach 5.67 trillion yuan, with a growth rate of 5.4%, which is better than expected [3] Investment and Infrastructure Development - A total of 255 billion yuan is planned for major engineering investments in 2023 [6] - Key infrastructure projects include the construction of various metro lines and the South-North Passage [6] Industry Development Initiatives - The report emphasizes the cultivation of future industries such as brain-computer interfaces and fourth-generation semiconductors [4] - Implementation of the "Artificial Intelligence +" initiative to enhance smart manufacturing and technology integration [4] Financial and Capital Market Reforms - The report outlines plans to deepen financial system reforms and improve the connectivity of bond markets [7] - There is a focus on nurturing long-term and patient capital to support innovation and sustainable development [7] Social Services and Community Support - The report includes plans to reform elderly care services, adding 2,000 cognitive care beds and 200 community elderly service stations [7]